Diligence report Precision-fermented structural protein materials and bio-based textiles Private unicorn

Spiber

Spiber Startup Diligence Report

Advance only to confirmatory diligence with a heavy focus on financing, production economics, and commercialization proof. Spiber may have defensible technology and strategic partner interest in a large materials transition, but the 2025 business-support contract and 2026 New Spiber launch signal a company still working through monetization, production-capacity optimization, capital allocation, and technical bottlenecks. Underwriting should depend on direct evidence that Brewed Protein can scale at acceptable cost, produce repeat revenue beyond limited capsules/collaborations, and preserve IP/customer/supplier continuity through the new structure.

Company profile

Spiber Startup Diligence Report

Spiber is an active Japan-headquartered private unicorn in precision-fermented structural protein materials. Public evidence supports a real company with current leadership, Japan and Thailand operating footprint, product launches with recognizable apparel brands, a substantial scientific publication record, disclosed patents, sustainability positioning, and recent 2025-2026 corporate actions. The diligence conclusion is high-potential but high-risk: the public record validates technology ambition and market interest, while the most investment-critical facts - revenue, gross margin, plant economics, cash runway, debt, cap table, customer concentration, and post-restructuring continuity - are not publicly verifiable.

Website: spiber.inc
Sector: Precision-fermented structural protein materials and bio-based textiles
Geography: Japan-headquartered with manufacturing in Japan and Thailand and business development in Europe
Stage: Private unicorn
Known aliases: Spiber Inc., Spiber K.K., Spiber株式会社, Spiber (Thailand) Ltd., New Spiber, Brewed Protein
Report version: 1.0
Timezone: Asia/Tokyo

Executive summary

Strengths

The public unicorn list identifies Spiber as a Japan biotechnology unicorn valued at US$1.22 billion in September 2021, and CB Insights lists Spiber as alive with US$1.068 billion total raised.
Spiber-owned pages describe Brewed Protein fiber, product applications across apparel categories, R&D-stage protein finishes/surfaces, food proteins, and precision fermentation.
Spiber's creations and news pages show numerous public product collaborations, including The North Face, Goldwin, JNBY/CROQUIS, Bonmax, Untouched World, Issey Miyake, Burberry, Vollebak, PANGAIA, and others.

Risks

Financial quality, runway, debt, revenue scale, gross margin, and restructuring economics are not public and are particularly important after 2025-2026 support and New Spiber actions.
Manufacturing scale and unit economics remain the core technical/commercial gating issue for precision-fermented structural protein materials.
Customer traction is visible through collaborations, but revenue concentration, repeat purchasing, conversion from capsule products to scale orders, and pricing power are not public.

Gaps

Audited financial statements, monthly management accounts, revenue by product/customer/geography, gross margin, unit cost per kilogram, burn, cash, debt, and runway.
Current cap table, debt stack, liquidation preferences, excluded assets in the New Spiber succession, investor rights, option plans, and legal entity chart.
Plant capacity, utilization, yield, uptime, quality metrics, capex plan, cost curves, and supply agreements for Japan, Thailand, and partner manufacturers.
Customer contracts, sales pipeline, order volumes, repeat rates, sell-through, channel economics, and concentration by brand or strategic partner.
Patent assignments, freedom-to-operate opinions, litigation searches, regulatory correspondence, insurance schedules, employment contracts, and safety/environmental records.

Recommended next steps

Run financial, legal, and restructuring diligence before relying on the 2021 unicorn valuation.
Perform a production-economics workstream covering facility capacity, cost per kilogram, quality, capex, and supply-chain dependencies.
Reference-check major brand, supplier, and strategic partners and reconcile public collaborations to revenue, margins, and reorder behavior.
Review IP ownership, patent prosecution, trade-secret controls, environmental/safety compliance, LCA substantiation, privacy controls, and material contracts.

Risk register

critical high likelihood

R-001: Financial viability and restructuring economics

Revenue, margin, burn, cash, debt, runway, and restructuring economics are not public, and recent releases emphasize commercialization reset, early monetization, and profitability.

Diligence request: Require audited statements, monthly management accounts, cash/debt/runway, financing and succession documents, and a board-approved forecast before underwriting.

high high likelihood

R-002: Manufacturing scale and unit-cost risk

Spiber has disclosed mass-production infrastructure and product forms, but public sources do not reveal capacity, utilization, yield, cost per kilogram, quality, capex, or uptime.

Diligence request: Run plant diligence on capacity, yield, cost, uptime, quality, capex, feedstock, utilities, and partner-manufacturer SLAs.

high medium likelihood

R-003: Customer traction and concentration economics

Public collaborations are numerous, but top customer revenue, repeat purchases, sell-through, contract commitments, and concentration are not public.

Diligence request: Request top-customer revenue, reference calls, contracts, purchase orders, reorder history, margins, and pipeline by account.

high medium likelihood

R-006: Technical bottlenecks and R&D execution

Spiber's 2026 release explicitly assigns founders to resolve technical challenges and accelerate commercialization, implying key technical work remains.

Diligence request: Request technical risk register, R&D roadmap, stage gates, founder retention terms, failure-mode analysis, and customer qualification data.

high medium likelihood

R-007: Leadership transition and business succession risk

New Spiber launched with a new CEO and succession from Former Spiber except certain operations; this may affect assets, liabilities, people, contracts, governance, and IP.

Diligence request: Review succession documents, excluded assets, consents, retention, governance, board minutes, and 100-day execution KPIs.

high unknown likelihood

R-008: Legal, IP, regulatory, insurance, and contract gaps

Material legal records, docket searches, IP assignments, insurance schedules, material contracts, and regulatory correspondence are not publicly verifiable.

Diligence request: Obtain counsel letters, docket searches, IP schedules, assignments, FTO opinions, insurance schedules, material contracts, and regulator correspondence.

medium high likelihood

R-004: Competitive substitutes and pricing pressure

Spiber competes with bio-based materials peers and incumbent fibers that may offer lower price, existing supply chains, or adequate sustainability narratives.

Diligence request: Benchmark price, performance, sustainability claims, supply assurance, brand willingness to pay, and win/loss data against substitutes.

medium medium likelihood

R-005: Supply-chain, feedstock, and cross-border operating dependency

Feedstock sourcing, Thailand operations, partner textile conversion, renewable-electricity claims, and cross-border logistics may affect continuity and margins.

Diligence request: Review supplier agreements, qualified alternatives, input price exposure, plant permits, tax/customs, logistics, and business continuity plans.

Chapter 01

01Financial Information

Public sources verify Spiber's 2021 unicorn valuation, CB Insights alive status, total raised, last raised amount, and recent corporate restructuring signals. They do not disclose revenue, margin, cash, burn, debt, runway, customer backlog, tax position, or cap-table economics.

EC-001 EC-002 EC-009 EC-010 EC-013

I.A Annual and quarterly financial information for the past three years

not publicly verifiable confidence: low

No audited financial statements, quarterly management reports, product gross-margin breakdown, backlog, or accounts-receivable aging schedules were located in public sources. CB Insights redacts revenue, and Spiber's own pages emphasize products, sustainability, and corporate updates rather than financial statements.

EC-006 EC-013 EC-014

Evidence gaps

Audited FY2023-FY2025 statements, monthly management accounts, revenue recognition policy, AR aging, backlog, cash, debt, burn, and runway.

Hidden risks

Collaborations could represent low-volume capsule launches, subsidized pilots, or brand marketing rather than durable, profitable revenue.
Manufacturing startups can consume significant capital before stable yield and utilization are reached.

Follow-up questions

What were FY2023-FY2025 revenue, gross margin, EBITDA, operating cash flow, cash, debt, burn, runway, backlog, and AR aging?

Public revenue and unit-economic signals
metric	public signal	verification status	private data request
Revenue	CB Insights revenue field is redacted; no company revenue disclosure located.	not_publicly_verifiable	Audited revenue and monthly revenue by product, customer, channel, and geography.
Gross margin and unit cost	No material unit economics disclosed.	not_publicly_verifiable	Cost per kilogram, gross margin by product, yield, utilization, scrap, warranty, logistics, and quality cost.
Customer traction	40-plus brands and 200-plus items claimed; many product launches listed.	partially_verified	Revenue by account, repeat orders, sell-through, margins, and signed purchase commitments.
Runway and burn	Not public; management support release references capital investment and resource deployment.	not_publicly_verifiable	Cash, debt, burn, capex budget, financing plan, and runway.

This table intentionally includes not-publicly-verifiable rows because financial statements were not available.

I.B Financial Projections

partially verified confidence: medium

Public evidence provides valuation and funding anchors, but not board-approved projections. The 2025 business-support release explicitly references re-optimizing production capacity, capital investment, management resources, and commercial strategy, and the 2026 release emphasizes early monetization and profitability.

EC-001 EC-002 EC-009 EC-010

Evidence gaps

Board-approved forecast, sensitivity cases, capex plan, financing plan, debt covenants, and assumptions for price, yield, utilization, and customer orders.

Hidden risks

The 2021 unicorn mark may be stale if later financing, debt, liquidation preferences, or business succession changed the economic claims.
References to re-optimizing capacity and early monetization may indicate prior production or commercialization gaps.

Follow-up questions

What financing, debt, restructuring, valuation, or investor-rights changes occurred after the September 2021 unicorn round?

Public funding and valuation history
date or period	event	amount or valuation	evidence	diligence caveat
September 2021	Unicorn valuation	US$1.22B	Public unicorn list row for Spiber lists valuation, date, sector, and country.	Need actual round documents and post-money calculation.
CB Insights current profile	Total capital raised	US$1.068B total raised	CB Insights lists total raised and alive stage.	Need round-by-round securities and current capitalization.
Approximately 2024 by CB Insights page age	Last raised	US$65.26M	CB Insights lists last raised as US$65.26M, 2 years ago.	Need instrument, terms, use of proceeds, and whether debt or equity.
2025-2026	Business support and New Spiber launch	Not disclosed	Spiber disclosed business support and a new management/business-succession structure.	Need legal and economic effect on existing securities and obligations.

Amounts are public-source anchors, not verified against financing documents.

Spiber public financing and restructuring timeline Timeline of public valuation, funding, business support, and New Spiber events.

Not all financings are public.

Public funding and valuation anchors Bar chart comparing public total raised, 2021 valuation, last raised amount, and unavailable revenue.

Amounts are public-source values, not audited.

I.C Capital Structure

not publicly verifiable confidence: low

CB Insights lists representative investors including Kanematsu, Komatsu Matere, Cool Japan Fund, The Yamagata Bank, and Tokyo Century, but public sources do not disclose current shares outstanding, option pools, warrants, debt instruments, bank lines, off-balance-sheet liabilities, liquidation preferences, or ownership percentages.

EC-002 EC-009

Evidence gaps

Fully diluted cap table, option ledger, warrant/note schedule, shareholder agreements, debt agreements, succession documents, excluded assets, and intercompany agreements.

Hidden risks

Investors, creditors, or former-entity stakeholders may hold rights that materially affect future financing and exit proceeds.
Excluded operations or assets could alter IP, customer contracts, manufacturing rights, or liabilities.

Follow-up questions

Provide the current legal-entity chart, cap table, debt stack, option plan, liquidation waterfall, and New Spiber asset/liability transfer schedule.

Capital structure and ownership snapshot
stakeholder or item	public position	verification status	required request
Named investors	CB Insights names Kanematsu, Komatsu Matere, Cool Japan Fund, The Yamagata Bank, Tokyo Century and additional investors.	partially_verified	Investor ledger, ownership percentages, security classes, investor rights.
Shares, options, warrants	Not public	not_publicly_verifiable	Fully diluted cap table, option plan, warrant/note schedule.
Debt and bank lines	Not public; external news snippets refer to debt-laden status but full article was not used as evidence.	not_publicly_verifiable	Debt schedule, covenants, liens, guarantees, maturity schedule.
Former/New Spiber assets and liabilities	New Spiber succeeded all businesses of Former Spiber except certain exceptions such as U.S. operations.	partially_verified	Succession agreement, excluded-asset/liability list, consents.

Capital structure is a high-priority private-data gap.

I.D Other financial information

partially verified confidence: medium

Tax position, accounting policies, revenue recognition, transfer pricing, and detailed equity/debt financing history are not public. Public evidence does support that the company is active and recently reorganized under New Spiber rather than IPO'd, acquired, or shut down.

EC-006 EC-009 EC-010 EC-013

Evidence gaps

Tax returns, tax provision, transfer-pricing files, revenue-recognition memos, grant/loan agreements, and complete financing ledger.

Hidden risks

Cross-border manufacturing and business-development operations may create transfer-pricing, VAT, customs, tax-credit, and grant-compliance exposures.

Follow-up questions

What are Spiber's current tax assets/liabilities, NOLs, transfer-pricing arrangements, grant obligations, accounting policies, and financing history?

Chapter 02

02Products

Spiber's public product evidence is stronger than its financial evidence. The company describes Brewed Protein fiber for multiple apparel applications, sells or routes short fibers, slivers, yarn, and textiles through Spiber and partners, and discloses R&D-stage protein finishes, surfaces, food proteins, and hair materials. Product-market acceptance and cost competitiveness remain the key open questions.

EC-003 EC-004 EC-005 EC-006 EC-007 EC-015

II.A Description of each product

partially verified confidence: medium

Brewed Protein fiber is publicly positioned for shirts, suits, outerwear, underwear, accessories, knitwear, and long-hair fur. Spiber also discloses product forms such as short fibers/slivers, spun yarn, and textiles, plus R&D-phase protein finish, protein-based surface/block copolymer, food proteins, and hair materials. Public pricing is limited to a few branded products, not enterprise material pricing or margin.

EC-004 EC-005 EC-006 EC-007 EC-015

Evidence gaps

Material specification sheets, pricing schedules, warranties, customer acceptance test results, defect rates, return rates, cost per kilogram, product gross margin, and roadmap milestones.

Hidden risks

The product portfolio may be broad but not yet economically repeatable if volumes are small, blends use low Brewed Protein percentages, or costs remain high.
Performance claims, biodegradability, odor control, and LCA benefits need claim-specific testing and legal substantiation.

Follow-up questions

Which products are commercial, pilot, or R&D; what are their current volumes, price per kilogram, gross margins, customer segments, and technical acceptance gates?

Product and application matrix
product or program	target application	public evidence	verification status	key gap
Brewed Protein fiber	Shirts, suits, outerwear, underwear, accessories, knitwear, long-hair fur.	Spiber protein page lists these apparel applications.	verified	Product-level volumes, performance, cost, and defect data.
Short fibers and slivers	Textile inputs.	Spiber says short fibers and slivers are available only from Spiber.	verified	Commercial price, MOQ, lead times, and quality specs.
Spun yarn and textiles	Yarn/textile supply through Spiber or partner companies/manufacturers.	Spiber product page describes partner availability.	verified	Partner contracts and supply assurance.
Protein finish and protein-based surface	Polyester finish, coatings, membranes, leather-like sheets.	Spiber product and innovation pages place these in R&D.	partially_verified	Stage-gate, cost-to-complete, and launch timing.
Food proteins	Functional proteins for food, feed, and beyond.	Spiber says proof-of-concept completed for several food proteins and it seeks partners.	partially_verified	Regulatory path, partners, economics, and product safety.

Commercial maturity varies by row.

Public pricing and composition signals
item	price or terms	composition or spec	diligence readthrough
Spiber Tee 001	JPY 9,900 to JPY 11,000 plus shipping; Japan-only purchase through official LINE.	93% cotton, 7% Brewed Protein fiber.	Useful retail proof point but not sufficient for bulk material pricing.
CROQUIS double-faced wool coat	Price not public in source.	Fine worsted wool yarn blended with 10% Brewed Protein fiber.	Brand adoption visible; material economics and volume unknown.
Untouched World SS2025 items	Price not public in Spiber source.	90% organic cotton, 10% Brewed Protein fiber.	Multiple SKUs support adoption; revenue per SKU unknown.
Enterprise material sales	Not public.	Short fibers, slivers, yarn, textiles, and R&D materials.	Need price list, MOQ, delivery, warranty, and margin schedule.

Blend percentages may materially affect revenue per finished product.

Brewed Protein product and manufacturing architecture Material flow from feedstock and fermentation to polymer, fibers, yarn/textiles, and end products.

Public evidence does not quantify throughput.

Chapter 03

03Customer Information

Public evidence shows numerous brand collaborations and strategic partner references, but it does not disclose top customers, revenue contribution, concentration, reorder behavior, or supplier purchase amounts. Brand proof points are real diligence leads, not substitutes for customer-contract and cohort data.

EC-003 EC-005 EC-006 EC-009 EC-014

III.A Top customers by application

partially verified confidence: medium

Spiber's creations and news pages list many apparel brand collaborations, including 2025 launches with JNBY/CROQUIS, Bonmax, and Untouched World. The evidence supports market interest and product availability, but not a ranked top-customer list or revenue contribution.

EC-006 EC-014 EC-015

Evidence gaps

Top 15 customers by revenue and application for FY2024-FY2026, purchase order history, repeat order rates, sell-through, returns, and gross margin by customer.

Hidden risks

Visible logos may be limited-run collaborations rather than scaled recurring accounts.
Low Brewed Protein blend percentages may limit revenue per finished product.

Follow-up questions

Which customers account for at least 5% of revenue, what products did they buy, and what are renewal/reorder commitments?

Publicly known customer and brand product launches
brand or customer	year or date	product or use case	public evidence	open question
JNBY Group / CROQUIS	2025	Wool coats using Brewed Protein fiber.	Spiber news says this was the first adoption by a Chinese fashion brand.	Order volume, commercial terms, and planned expansion across JNBY portfolio.
Bonmax	2025	Spiber Tee 001 products.	Spiber news describes Bonmax collaboration and public prices.	Units sold, inventory risk, gross margin, and reorder plans.
Untouched World	2025	Four Spring/Summer items with Brewed Protein fiber.	Spiber news describes four items using 90% organic cotton and 10% Brewed Protein fiber.	Wholesale pricing, sell-through, and next-season commitment.
The North Face / Goldwin	2019-2026	Moon Parka and multiple later creation entries.	Spiber creations page lists multiple The North Face/Goldwin products.	Long-term contract status and revenue contribution.
Other visible brands	2020-2026	Issey Miyake, Burberry, Vollebak, PANGAIA, sacai, Yohji Yamamoto, YOKE, Woolrich Outdoor Label, United Arrows, and others.	Spiber creations page lists numerous capsule/project entries.	Which are active paying accounts and which were one-off marketing collaborations?

This is not a top-customer revenue table.

Customer concentration proxy by public evidence type Bar chart showing public customer evidence counts and key unknowns.

40-plus and 200-plus are lower-bound company-published counts.

III.B Strategic relationships

partially verified confidence: medium

Public strategic relationships include manufacturing, commercial, R&D, and application partners. The 2026 New Spiber release lists supportive comments from partners including Aderans, Amano Enzyme, Kaji Group, Kanematsu, Kansai Paint, Keio University IAB, KISCO, Kojima Industries, Komatsu Matere, Goldwin, Shima Seiki, Haseko Textile, and Sumitomo Mitsui Construction.

EC-007 EC-009 EC-014

Evidence gaps

Executed partner agreements, revenue contribution, exclusivity, termination rights, IP ownership terms, co-development budgets, and marketing obligations.

Hidden risks

Public partner comments do not prove binding revenue commitments, exclusivity, minimum purchases, or margin sharing.

Follow-up questions

Which strategic relationships are revenue-generating, which are R&D-only, and what are the termination/exclusivity/IP terms?

Strategic relationships and partner evidence
partner	relationship type	evidence	contract gap
Aderans	Hair-material R&D/application partner.	Spiber innovation page and New Spiber release reference hair material collaboration.	IP ownership, milestone payments, exclusivity, commercialization plan.
Komatsu Matere	Investor and materials/application partner.	CB Insights names investor; New Spiber release includes partner comment.	Investment terms, supply/manufacturing terms, IP and exclusivity.
Kanematsu	Investor/strategic partner.	CB Insights names investor; New Spiber release includes supportive comment.	Commercial role, governance rights, financing terms.
Goldwin	Longstanding apparel brand/product partner.	New Spiber partner comment and creations page product history.	Minimums, exclusivity, revenue share, supply commitments.
Kansai Paint / Kojima Industries / Sumitomo Mitsui Construction	Adjacent application partners.	New Spiber release includes partner comments around coatings, automotive, and construction.	Application-specific development milestones, regulatory path, and revenue model.

Partner comments do not prove binding purchase commitments.

III.C Revenue by customer

not publicly verifiable confidence: low

Revenue by customer is not publicly verifiable. Publicly visible collaborations should be reconciled to booked revenue, shipped volume, repeat orders, and pipeline status before assessing concentration.

EC-014

Evidence gaps

Revenue by customer, product, application, geography, and channel; gross margin by customer; contract term and renewal status.

Hidden risks

A small number of partners or brand groups could account for most revenue, technical validation, or public credibility.

Follow-up questions

Provide customer-level revenue, gross margin, concentration, contract status, and forecast for the last two fiscal years and current year-to-date.

III.D Significant relationships severed within the last two years

not publicly verifiable confidence: low

No public evidence was found identifying significant customer, partner, or supplier relationships severed within the last two years. The New Spiber business succession and U.S. operations carve-out require direct confirmation of any discontinued relationships.

EC-009 EC-014

Evidence gaps

Lost customer/partner/supplier list, churn reasons, settlement documents, transfer consents, and termination notices.

Hidden risks

Excluded operations, amended agreements, or partner fatigue may not be visible in public news.

Follow-up questions

Were any material customers, partners, suppliers, or research collaborators terminated, transferred, or renegotiated during 2024-2026?

III.E Top suppliers

partially verified confidence: medium

Supplier economics are not public. Spiber discloses Thailand polymer production using Bonsucro-certified sugarcane-derived sugar and a selective disclosure approach for supplier detail, while the product page says yarn and textiles may come from Spiber or partner manufacturers.

EC-003 EC-004 EC-005

Evidence gaps

Top supplier list, purchase amounts, minimum commitments, single-source dependencies, quality agreements, sustainability audits, and business continuity plans.

Hidden risks

Raw-material price, fermentation inputs, utilities, contract manufacturers, and logistics dependencies may create bottlenecks or margin volatility.

Follow-up questions

Who are the top suppliers by spend and criticality, what are the contract terms, and how many have qualified alternatives?

Supplier and manufacturing dependency snapshot
dependency	role	public evidence	risk
Spiber Thailand	Fermentation mass-production plant and polymer manufacturing.	Spiber company page discloses Thailand subsidiary, Rayong location, and plant role.	Capacity, cost, regulatory, utility, labor, logistics, and political/currency exposure.
Japan operations and partner manufacturers	HQ/prototyping; spinning, textiles, and product manufacture through Spiber and partners.	Spiber company and product pages disclose Japan locations and partner availability.	Partner quality, scale, and contract continuity.
Bonsucro-certified sugarcane-derived sugar	Fermentation feedstock for Thailand polymer production.	Spiber sustainability page identifies Bonsucro-certified sugarcane-derived sugar.	Input price/availability, certification continuity, and substitution with non-edible sugar.
Renewable electricity attribute certificates	Sustainability/LCA claim assumption and operational footprint.	Spiber says it uses 100% renewable electricity via energy attribute certificates since 2023.	Claim substantiation and actual production-run environmental impact.

Supplier spend and contractual concentration are not public.

Chapter 04

04Competition

Spiber competes across bio-based textile manufacturing, precision fermentation, performance apparel inputs, leather-like materials, coatings, food proteins, and conventional natural/synthetic fibers. Public evidence supports leadership recognition in CB Insights' bio-based textile manufacturing landscape, but relative cost/performance and market share are not public.

EC-002 EC-004 EC-005 EC-016

IV.A Competitive landscape by market segment

partially verified confidence: medium

CB Insights names Spiber a leader in bio-based textile manufacturing and identifies competitors/adjacent companies including Tandem Repeat, Newlight Technologies, Natural Fiber Welding, and MycoWorks. Spiber's differentiation is structural protein design, fermentation, publications, patents, and brand collaborations, but customers can still choose conventional wool, cashmere, cotton, synthetics, recycled synthetics, mycelium/leather alternatives, and other engineered biomaterials.

EC-002 EC-004 EC-005 EC-016

Evidence gaps

Market share, win/loss data, customer benchmark tests, competitor price curves, switching costs, and quantified technical advantages.

Hidden risks

Even technically superior materials may lose to incumbent fibers on price, supply assurance, design familiarity, certifications, or consumer demand.
Brand partners may use multiple sustainability materials and avoid single-supplier dependency.

Follow-up questions

What are Spiber's quantified cost, performance, sustainability, supply assurance, and brand-conversion advantages over competing materials?

Competitor and substitute comparison
entity or substitute	segment	public evidence	diligence question
Spiber	Precision-fermented structural protein fibers and biomaterials.	CB Insights names Spiber a leader in bio-based textile manufacturing.	Can it scale at competitive cost and win repeat volume?
Tandem Repeat	Alternative protein/materials competitor.	CB Insights lists Tandem Repeat as a competitor.	How do performance, cost, IP, and customers compare?
Newlight Technologies, Natural Fiber Welding, MycoWorks	Bio-based textile/material alternatives.	CB Insights names these among companies in the bio-based textile manufacturing landscape.	Which applications overlap with Spiber's customers and price points?
Conventional wool, cashmere, cotton, synthetics, recycled materials	Incumbent and lower-cost substitutes.	Spiber product pages position Brewed Protein relative to silk, cashmere, wool, cotton blends, and synthetics.	What premium will brands/consumers pay, and at what supply assurance?

Competitor financials and prices were not independently benchmarked in this run.

Basis of competition scoring
axis	spiber public position	evidence status	risk readthrough
Technology and IP	Strong public signals: 122 patents and long publication list.	partially_verified	Need FTO, assignments, and commercial relevance of patent claims.
Brand adoption	Many visible apparel collaborations.	partially_verified	Need scale and repeat purchasing.
Cost and scale	Mass-production infrastructure disclosed but economics absent.	not_publicly_verifiable	Core underwriting risk.
Sustainability	Strong published LCA reductions and sourcing claims, but assumption-heavy.	partially_verified	Need third-party assurance and current production-run data.

Scores are qualitative because public data is incomplete.

Bio-based materials market map Market positioning by application breadth and production maturity using public evidence.

Positioning is qualitative.

Chapter 05

05Marketing, Sales, and Distribution

Spiber's go-to-market motion appears partnership-led: direct material sales/business development, co-development with textile and brand partners, public capsule launches, trade shows, and selective direct-to-consumer proof points. Public evidence does not reveal marketing budget, sales productivity, pipeline, CAC, quota, sales cycle, or channel conversion.

EC-003 EC-006 EC-009 EC-014 EC-015

V.A Strategy and implementation

partially verified confidence: medium

Public evidence indicates Spiber uses material sales/business development, brand collaborations, partner manufacturing channels, trade-show/news activity, and occasional direct consumer access such as Japan-only LINE purchase for Spiber Tee 001. Channel weights, conversion rates, and budget efficiency are not public.

EC-003 EC-006 EC-014 EC-015

Evidence gaps

Marketing budget, pipeline, conversion by channel, CAC, sales cycle, sales territories, quota attainment, trade-show ROI, and co-marketing agreements.

Hidden risks

Marketing visibility may not convert into repeat material orders if pricing, supply continuity, or consumer demand remain weak.
A partner-led GTM can create dependency on brand calendars and fashion-season cycles.

Follow-up questions

What are the current GTM channels by revenue, pipeline, conversion rate, average sales cycle, and gross margin?

Distribution channels and GTM motions
channel	public evidence	likely role	gap
Direct material sales and business development	Spiber Europe is described as promoting material sales/business in Europe.	Enterprise/B2B material sales.	Revenue, pipeline, sales cycle, and account list.
Brand collaborations	Creations and news pages list collaborations across many brands.	Demand creation, validation, co-marketing, and possible revenue.	Volume, margin, repeat order, and contract terms.
Partner manufacturing	Product page says yarn/textiles are available from Spiber or partner companies/manufacturers.	Scale channel for textile conversion.	Capacity, SLAs, quality, and exclusivity.
Direct-to-consumer proof point	Spiber Tee 001 available through official LINE in Japan.	Awareness and consumer validation rather than primary channel.	Units sold, CAC, and inventory economics.

Channel weights are not publicly disclosed.

Public marketing-signal summary
signal	evidence	strength	caveat
Recent news cadence	2025-2026 product launches and leadership updates on Spiber news/creations pages.	Medium	Cadence does not equal revenue.
Brand prestige	Public creations include luxury/outdoor/fashion names.	Medium	Need reference calls and purchase volumes.
Sustainability positioning	Spiber publishes LCA reductions, net-zero target, and sustainable sourcing claims.	Medium	Claims are assumption-heavy and need substantiation.
Market-database recognition	CB Insights names Spiber a leader in bio-based textile manufacturing.	Medium	Analyst recognition is not customer conversion.

Marketing signals are primarily company-published.

GTM channel mix proxy Bar chart of public GTM signal categories rather than revenue weights.

Scores are ordinal based on visible public evidence.

V.B Major Customers

not publicly verifiable confidence: low

Major customer status and growth prospects are not publicly verifiable. Brand collaborations provide reference targets for diligence, especially Goldwin/The North Face, JNBY Group, Bonmax, Untouched World, Issey Miyake, and other recurring public examples.

EC-006 EC-014

Evidence gaps

Customer pipeline, contract status, forecast by customer, renewal/reorder data, and lost-deal analysis.

Hidden risks

Future growth may depend on a small number of strategic accounts moving from capsules to scaled seasonal programs.

Follow-up questions

Which brand partners are expected to generate scaled repeat revenue over the next 24 months, and under what commitments?

V.C Principal avenues for generating new business

partially verified confidence: medium

New business likely comes from strategic partner co-development, direct materials sales, Europe business development, public brand launches, R&D collaborations, and proof-point products. The evidence base is public but not quantitative.

EC-009 EC-014

Evidence gaps

Lead sources, qualified pipeline, target accounts, customer acquisition costs, conversion rates, and expected launch calendars.

Hidden risks

If the commercialization reset is early-stage, near-term pipeline may not support current valuation expectations.

Follow-up questions

Provide a pipeline report by avenue, stage, expected launch, expected revenue, probability, and responsible owner.

V.D Sales force productivity model

not publicly verifiable confidence: low

Sales compensation, quotas, sales cycle, and hiring plan were not public. Public leadership names business development and brand/communications executives, but not sales-force productivity metrics.

EC-003 EC-014

Evidence gaps

Sales team roster, compensation plans, quotas, pipeline coverage, sales cycle, technical support load, and new-hire productivity plan.

Hidden risks

Technical material sales may require long co-development cycles and intensive support, delaying revenue conversion.

Follow-up questions

What is the sales productivity model by role, region, partner type, quota, sales cycle, and technical-support hours per opportunity?

V.E Ability to implement marketing plan with current and projected budgets

not publicly verifiable confidence: low

Budget sufficiency is not publicly verifiable. The 2025 business-support release explicitly references deployment of management resources and resetting commercial strategy, suggesting budget/resource allocation should be a priority diligence topic.

EC-010

Evidence gaps

Marketing budget, sales headcount plan, working-capital plan, launch calendar, and budget-to-pipeline conversion evidence.

Hidden risks

Marketing and commercialization may be underfunded relative to manufacturing scale-up and R&D demands.

Follow-up questions

How much budget is allocated to GTM versus R&D/manufacturing, and which initiatives are funded or deferred?

Chapter 06

06Research and Development

Spiber has strong public R&D signals: precision-fermentation platform claims, 2015-2025 academic publication listings, patents, R&D-stage product areas, and a 2026 role shift keeping founders focused on technical bottlenecks and commercialization. The key risk is whether R&D progress translates into scalable, profitable manufacturing and product qualification.

EC-007 EC-008 EC-009 EC-011

VI.A Description of R&D organization

partially verified confidence: medium

Public leadership identifies Li Jiang as head of R&D and founders Kazuhide Sekiyama and Junichi Sugahara as principal researchers/CEO office. The 2026 release states founders stepped back from frontline management to resolve technical challenges and accelerate product development and commercialization.

EC-003 EC-009

Evidence gaps

R&D org chart, budgets, milestones, stage gates, technical risk register, defect/yield root causes, and key-person retention agreements.

Hidden risks

Founder role changes can preserve technical continuity or indicate prior bottlenecks that management could not resolve at commercial pace.

Follow-up questions

What are the current R&D milestones, owners, budget, success criteria, top technical blockers, and expected dates?

R&D personnel and leadership signals
person or role	public position	source	diligence gap
Li Jiang	R&D head.	Spiber company page.	Biography, team size, milestone ownership, retention terms.
Kazuhide Sekiyama	Founder/principal researcher/CEO office after stepping back from frontline management.	Company page and New Spiber release.	Founder retention, IP assignment, technical blocker ownership.
Junichi Sugahara	Founder/principal researcher/CEO office after stepping back from frontline management.	Company page and New Spiber release.	Founder retention, IP assignment, technical blocker ownership.
Academic/research contributors	Publications list shows multiple Spiber-linked scientific outputs from 2015-2025.	Academic papers page.	Employment/assignment status, key-person dependency, and sponsored-research IP terms.

Only roles/publications are verified, not personnel file details.

VI.B New Product Pipeline

partially verified confidence: medium

Public pipeline areas include R&D-stage protein finish for polyester, protein-based surfaces/block copolymers for coatings/membranes/leather-like materials, food proteins after proof-of-concept, and hair materials with Aderans. Development cost, critical path, regulatory requirements, and launch timing are not public.

EC-007 EC-008 EC-011

Evidence gaps

Pipeline stage gates, technical readiness levels, cost-to-complete, IP clearance, regulatory pathway, partner commitments, and commercialization dates.

Hidden risks

Food, healthcare, hair, coating, and leather-like applications may introduce different regulatory, qualification, manufacturing, and customer-adoption risks.

Follow-up questions

For each pipeline program, what are the launch criteria, remaining technical risks, capex needs, regulatory needs, partner obligations, and expected revenue timing?

Public product and research pipeline
pipeline area	public status	evidence	principal risk
Protein finish for polyester	R&D-stage material.	Protein and innovation pages describe natural touch, odor control, moisture-regulating benefits, electrostatic improvement, and affordability goals.	Commercial performance and cost at scale.
Protein-based surface/block copolymer	R&D-stage material for coatings, membranes, and leather-like sheets.	Protein and innovation pages describe protective functions and leather-like material potential.	Different end markets may need separate certification and scale-up.
Food proteins	Proof-of-concept completed for several types; scaling and seeking partners.	Innovation page.	Food/feed regulatory, safety, taste, and cost hurdles.
Hair materials	Collaboration with Aderans.	Innovation page and New Spiber partner comment.	Application-specific qualification and commercial adoption.
Structural protein fiber IP	122 patents and at least one granted protein fiber production method patent in CB Insights profile.	CB Insights patent section.	FTO, assignments, and commercial relevance.

Public status does not include cost-to-complete.

R&D portfolio architecture R&D portfolio map from platform technology to product programs.

Does not imply all programs are commercial.

Chapter 07

07Management and Personnel

Spiber publicly discloses a current executive roster, CEO Maya Kawana, R&D/manufacturing/business/finance/HR/brand leaders, Europe branch representative, Thailand directors, and founder role changes. Headcount, compensation, incentive plans, employee relations, and turnover are not public.

EC-003 EC-009 EC-010

VII.A Organization Chart

partially verified confidence: medium

Spiber's company page and 2026 release support a high-level management structure, with Maya Kawana as CEO, Daniel Meyer as strategy/finance head, and leaders for HR/general affairs, R&D, business development, manufacturing, and brand/communications.

EC-003 EC-009

Evidence gaps

Full org chart, board composition, reporting lines, delegated authorities, key-person dependencies, and succession plans.

Hidden risks

Public org charts do not show board oversight, decision rights, succession plans, retention risks, or post-restructuring role clarity.

Follow-up questions

Provide the current board and management org chart, decision-rights matrix, succession plan, and key-person risk analysis.

Public management structure High-level org chart using publicly listed management roles.

Formal reporting lines are inferred from executive roles and should be confirmed.

VII.B Historical and projected headcount by function and location

not publicly verifiable confidence: low

Historical and projected headcount by function and location were not public. Public evidence supports multiple operating locations and leadership functions, but not employee counts or hiring plans.

EC-003

Evidence gaps

Headcount by function/location/month, open roles, hiring plan, attrition, contractor usage, and payroll by department.

Hidden risks

Manufacturing and R&D companies can have high fixed personnel cost and key-person concentration that are invisible without headcount data.

Follow-up questions

Provide historical and projected headcount by function and location for FY2023-FY2026.

Headcount and turnover evidence gaps
function or location	public anchor	verification status	request
Japan HQ and prototyping studio	Company page lists HQ and prototyping locations.	partially_verified	Headcount by function, payroll, attrition, and hiring plan.
Thailand plant	Company page lists Thailand plant and directors.	partially_verified	Plant headcount, shifts, safety, turnover, and contractor use.
Europe branch	Company page lists Spiber Europe in Paris for material sales/business promotion.	partially_verified	Sales/business-development headcount and pipeline ownership.
Turnover and employee relations	Not public; leadership transition disclosed.	not_publicly_verifiable	Turnover, regretted losses, employee relations, whistleblower data.

No public headcount count was found.

Headcount disclosure gap chart Chart showing locations with public site evidence but no public headcount counts.

This is a gap chart, not a headcount estimate.

VII.C Senior management biographies

partially verified confidence: medium

Spiber discloses senior management names and roles. The 2025 support release provides a public biography for Maya Kawana, including prior roles at Goldman Sachs Japan, Aoba-BBT, Afiniti Japan, BOLD, Ritsumeikan University, Design Future Japan, and Ai Robotics. Full biographies for other executives were not public in the reviewed sources.

EC-003 EC-009 EC-010

Evidence gaps

Full management bios, employment agreements, references, board evaluation materials, conflict disclosures, and key-person retention terms.

Hidden risks

A new CEO plus founder role changes can improve commercialization focus or create transition risk if responsibilities and retention are not aligned.

Follow-up questions

Provide senior management biographies, employment terms, prior company references, and conflict-of-interest disclosures.

Senior management roster
name	role	public bio signal	gap
Maya Kawana	CEO / Representative Director	Spiber company page lists CEO; 2025 and 2026 releases describe biography and CEO role.	Employment terms, authority, board role, KPI plan, conflicts.
Daniel Meyer	Strategy and finance head	Listed on Spiber company page.	Full biography and finance organization details.
Li Jiang	R&D head	Listed on Spiber company page.	Full biography, R&D budget, retention.
Jun Takigoshi	Business development head	Listed on Spiber company page.	Pipeline ownership and GTM plan.
Takayuki Muro	Manufacturing head	Listed on Spiber company page.	Plant KPIs, capacity, quality, and safety ownership.
Kazuhide Sekiyama and Junichi Sugahara	Principal researchers / CEO office	Company page lists roles; New Spiber release says founders focus on technical challenges and commercialization.	Founder agreements, IP assignments, retention, and technical milestones.

Management ages and full employment histories are not included because they were not necessary or not public for most executives.

VII.D Compensation arrangements

not publicly verifiable confidence: low

Compensation arrangements, benefit plans, severance, employment agreements, and bonus plans were not publicly verifiable.

EC-017

Evidence gaps

Employment agreements, benefit plans, bonus plans, retention awards, severance obligations, and change-of-control provisions.

Hidden risks

Retention, severance, change-of-control, and incentive misalignment may be material after a restructuring.

Follow-up questions

Provide executive and employee compensation arrangements, bonus plans, benefits, severance, and retention packages.

VII.E Incentive stock plans

not publicly verifiable confidence: low

Incentive stock plans and option ledgers were not publicly verifiable.

EC-017

Evidence gaps

Option plan, grant ledger, vesting schedules, exercise prices, refresh plan, and employee equity communication.

Hidden risks

Post-restructuring option refreshes or underwater options may create dilution and retention pressure.

Follow-up questions

Provide the incentive equity plan, grants, vesting, cancellations, repricing, and refresh plan.

VII.F Significant employee relations problems, past or present

not publicly verifiable confidence: low

No public evidence of significant employee-relations problems was found, but this was not independently verified through employee records or litigation databases.

EC-017

Evidence gaps

Employee complaints, disputes, internal investigations, whistleblower reports, labor relations, settlement agreements, and HR audit findings.

Hidden risks

Restructuring, plant scale-up, and leadership transition can create retention and employee-relations risk that may not appear publicly.

Follow-up questions

Provide employee-relations history, investigations, labor disputes, settlement agreements, and SpeakUp/whistleblower metrics.

VII.G Personnel Turnover

not publicly verifiable confidence: low

Personnel turnover data were not public. Founder role changes and a new CEO are public, but broader turnover, retention, benefit plans, and morale indicators require company records.

EC-009 EC-017

Evidence gaps

Monthly attrition by function/location, regretted-loss analysis, exit interviews, retention plans, and key-person contracts.

Hidden risks

Technical staff attrition could impair fermentation, polymer processing, and product qualification even if leadership continuity is presented positively.

Follow-up questions

What were attrition and regretted-loss rates by function and location for 2024-2026?

Chapter 08

08Legal and Related Matters

Public sources support IP activity, privacy/compliance statements, ISO certifications, sustainability policies, and recent business-succession facts. They do not disclose pending litigation, initiated litigation, insurance coverage, material contracts, regulatory correspondence, safety incidents, or full environmental liabilities.

EC-003 EC-005 EC-009 EC-011 EC-012 EC-018

VIII.A Pending lawsuits against the Company

not publicly verifiable confidence: low

No public evidence of pending lawsuits against Spiber was identified in reviewed public company pages or accessible sources, but authenticated docket searches were not performed.

EC-018

Evidence gaps

Counsel litigation letter, docket searches, claims register, settlement agreements, and threatened-claim schedule.

Hidden risks

Litigation could exist in jurisdictions or databases not accessible in this public-source run.

Follow-up questions

Provide counsel's litigation letter and a schedule of threatened, pending, settled, or indemnified claims.

Legal, regulatory, and IP matter summary
matter type	public evidence	verification status	diligence request
Pending lawsuits against company	No public lawsuit disclosure found in reviewed sources.	not_publicly_verifiable	Counsel letter and docket searches.
Pending lawsuits initiated by company	No public lawsuit disclosure found in reviewed sources.	not_publicly_verifiable	Docket and counsel schedule.
Patents	CB Insights lists 122 patents and a granted protein fiber production method patent.	partially_verified	Patent family, assignment, FTO, licenses, and encumbrances.
Privacy and data protection	Spiber privacy policy states Japanese law/GDPR compliance and security safeguards.	partially_verified	DPA, incident log, data map, DPIA, subprocessor and cross-border transfer review.
Environmental and safety	ISO9001/ISO14001 certifications and sustainability policies disclosed.	partially_verified	Permits, inspections, incidents, waste, worker safety, LCA substantiation.

Authenticated docket and regulator searches were not performed.

Legal, IP, and regulatory timeline Timeline of public legal/IP/regulatory-adjacent events relevant to diligence.

Absence of lawsuit events is not proof no lawsuits exist.

Spiber diligence risk heatmap Severity/likelihood heatmap for the full risk register.

Likelihood ratings reflect public evidence and gaps, not management-confirmed probabilities.

VIII.B Pending lawsuits initiated by Company

not publicly verifiable confidence: low

No public evidence of pending lawsuits initiated by Spiber was identified in reviewed public sources; authenticated docket and counsel searches are required.

EC-018

Evidence gaps

Docket searches, counsel files, demand letters, and IP enforcement records.

Hidden risks

IP enforcement, supplier disputes, customer disputes, or employment claims could be non-public or in inaccessible databases.

Follow-up questions

Provide a schedule of lawsuits, arbitrations, administrative proceedings, demand letters, and IP enforcement matters initiated by Spiber.

VIII.C Environmental and employee safety issues and liabilities

partially verified confidence: medium

Spiber discloses ISO9001 and ISO14001 certifications for Japan and Thailand, sustainability sourcing commitments, Bonsucro-certified sugarcane-derived sugar in Thailand, renewable electricity attribute certificates, and LCA highlights. Detailed safety incidents, environmental permits, violations, and liabilities were not public.

EC-003 EC-005

Evidence gaps

Permits, audits, incident logs, OSHA/equivalent records, waste-disposal contracts, environmental insurance, third-party LCA assurance, and advertising-law review.

Hidden risks

Production chemicals, fermentation waste streams, Thailand plant permits, worker safety, and LCA claim substantiation need legal and operational review.

Follow-up questions

Provide environmental permits, safety logs, regulatory inspections, waste-management contracts, LCA substantiation, and claim-review memos.

VIII.D Material patents, copyrights, licenses, and trademarks

partially verified confidence: medium

CB Insights lists 122 patents and a protein fiber production method patent with application date September 30, 2019 and grant date April 14, 2026. Full patent-family, assignment, opposition, license, freedom-to-operate, and trade-secret reviews were not performed.

EC-011

Evidence gaps

Patent family list, assignments, encumbrances, licenses, prosecution history, opposition history, FTO opinions, trade-secret register, and trademark portfolio.

Hidden risks

Key IP could be assigned across former/new entities, licensed to partners, subject to encumbrances, or insufficient for freedom to operate.

Follow-up questions

Provide an IP schedule with owners, jurisdictions, priority dates, grants, pending applications, licenses, encumbrances, and FTO opinions.

VIII.E Insurance coverage and material exposures

not publicly verifiable confidence: low

Insurance coverage, deductibles, exclusions, claims history, product liability coverage, D&O coverage, cyber coverage, and environmental coverage were not publicly verifiable.

EC-018

Evidence gaps

Insurance policies, broker summaries, claims history, coverage exclusions, and indemnity obligations.

Hidden risks

Product liability, environmental, D&O, cyber, and recall coverage may be material for global biomaterials manufacturing.

Follow-up questions

Provide all insurance policies, claims history, loss runs, broker letters, and coverage gaps.

Material contracts and insurance gaps
category	public signal	verification status	request
Business support and New Spiber succession	2025 support contract and 2026 New Spiber succession announced.	partially_verified	Support agreement, succession agreement, excluded assets/liabilities, consents.
Customer/partner contracts	Brand collaborations and partner comments are public.	not_publicly_verifiable	Executed agreements, minimums, exclusivity, IP, warranties, termination.
Supplier/manufacturing contracts	Thailand plant, partner manufacturing, and feedstock sourcing claims are public.	not_publicly_verifiable	Supply agreements, manufacturing SLAs, qualification records, continuity plans.
Insurance	No public schedule found.	not_publicly_verifiable	D&O, product liability, environmental, cyber, property, workers compensation, claims history.

Material contract review is essential due to business succession and commercialization reset.

VIII.F Material contracts

not publicly verifiable confidence: low

Material contracts are not public. Public evidence references business support with Maya Kawana, strategic partner continuity, brand collaborations, supplier and manufacturing partners, but not executed terms, minimums, IP ownership, exclusivity, termination rights, or transfer consents.

EC-009 EC-010 EC-018

Evidence gaps

Customer contracts, supplier contracts, manufacturing agreements, support contract, partner agreements, leases, financing contracts, and consent/amendment schedules.

Hidden risks

Business succession may require consents or amendments for customer, supplier, R&D, IP, plant, and financing agreements.

Follow-up questions

Provide all material contracts, amendments, transfer consents, exclusivity terms, termination rights, and change-of-control provisions.

VIII.G Regulatory agency problems

not publicly verifiable confidence: low

No public regulatory agency problems were identified in reviewed sources. Spiber's privacy policy states compliance with Japanese law, GDPR, and other norms, and its sustainability page describes an anonymous grievance mechanism. Direct regulator searches and counsel confirmation were not completed.

EC-012 EC-018

Evidence gaps

Regulatory correspondence, inspection reports, privacy incidents, food/feed regulatory pathway documents, environmental/safety filings, sanctions/export checks, and advertising claim reviews.

Hidden risks

Biomanufacturing, food-protein, employee-safety, data-protection, advertising, import/export, and environmental claims may trigger regulator scrutiny.

Follow-up questions

Provide regulatory correspondence, inspection/audit history, privacy incident logs, food/feed regulatory analysis, and environmental/safety compliance records.

Evidence

Evidence claims
ID	Claim	Status	Sources
EC-001	Spiber appears on a public unicorn list as a Japan biotechnology company valued at US$1.22 billion in September 2021.	verified medium	SRC-001
EC-002	CB Insights lists Spiber as founded in 2007, alive, with US$1.068 billion total raised and US$65.26 million last raised.	verified medium	SRC-002
EC-003	Spiber publicly discloses current company operations, CEO Maya Kawana, Japan HQ/prototyping locations, Europe branch, Thailand fermentation/polymer plant, executives, and ISO certifications.	verified high	SRC-003
EC-004	Spiber's product page describes Brewed Protein fiber applications, product forms, partner channels, and R&D-stage protein materials.	verified high	SRC-004
EC-005	Spiber publishes sustainability metrics and sourcing commitments, including 40-plus brands/200-plus items and LCA reductions, but frames LCA data as pre-production/future-looking and assumption-based.	partially verified medium	SRC-005
EC-006	Spiber's creations and news pages show numerous public product collaborations, including detailed 2025 launches with JNBY/CROQUIS, Bonmax, and Untouched World.	partially verified medium	SRC-007 SRC-011 SRC-012 SRC-013
EC-007	Spiber's innovation page describes precision fermentation, R&D-stage materials, food-protein proof-of-concept, and hair-material collaboration with Aderans.	verified medium	SRC-006
EC-008	Spiber lists academic publications from 2015 through 2025 across structural protein, biomaterials, silk, fermentation, and related research.	verified medium	SRC-008
EC-009	Spiber announced a 2026 New Spiber structure, business succession from Former Spiber except certain exceptions, Maya Kawana as CEO, and founders focused on technical challenges and commercialization.	verified high	SRC-009
EC-010	Spiber announced a 2025 business support contract with Maya Kawana, with comments emphasizing re-optimization of production capacity, capital investment, management resources, and commercial strategy.	verified high	SRC-010
EC-011	CB Insights lists Spiber as having filed 122 patents and shows a granted protein fiber production method patent.	partially verified medium	SRC-002
EC-012	Spiber publishes privacy safeguards and states compliance with Japanese law, GDPR, and other norms.	partially verified medium	SRC-014
EC-013	Spiber's revenue, financial statements, margin, burn, cash, debt, runway, and detailed unit economics are not publicly verifiable from reviewed sources.	not publicly verifiable high	SRC-002 SRC-003 SRC-004 SRC-009 SRC-010
EC-014	Customer-level revenue, concentration, reorder behavior, and pipeline are not publicly verifiable despite visible brand collaborations.	not publicly verifiable high	SRC-007 SRC-011 SRC-012 SRC-013
EC-015	Public pricing is limited to select finished products, while enterprise material pricing and economics are not public.	partially verified medium	SRC-004 SRC-011 SRC-012 SRC-013
EC-016	CB Insights identifies Spiber as a leader in bio-based textile manufacturing and names adjacent competitors/substitutes.	verified medium	SRC-002
EC-017	Headcount, compensation, incentive plans, employee relations, and turnover are not publicly verifiable from reviewed sources.	not publicly verifiable high	SRC-003 SRC-009
EC-018	Pending litigation, initiated litigation, insurance coverage, material contracts, and regulatory agency problems were not publicly verifiable from reviewed sources.	not publicly verifiable high	SRC-003 SRC-009 SRC-010 SRC-014

Sources
ID	Publisher	Title	Accessed
SRC-001	Wikipedia	List of unicorn startup companies	2026-05-16
SRC-002	CB Insights	Spiber - Products, Competitors, Financials, Employees, Headquarters Locations	2026-05-16
SRC-003	Spiber	Spiber Company	2026-05-16
SRC-004	Spiber	Spiber Protein	2026-05-16
SRC-005	Spiber	Spiber Sustainability	2026-05-16
SRC-006	Spiber	Spiber Innovation	2026-05-16
SRC-007	Spiber	Spiber Our creations	2026-05-16
SRC-008	Spiber	Spiber Academic papers	2026-05-16
SRC-009	Spiber	Spiber Launches Under New Leadership	2026-05-16
SRC-010	Spiber	Spiber Inc. signed a contract regarding business support	2026-05-16
SRC-011	Spiber	Spiber Launches Collaboration with JNBY Group	2026-05-16
SRC-012	Spiber	Spiber Tee 001 now available	2026-05-16
SRC-013	Spiber	Untouched World launches Spring/Summer 2025 collection featuring Brewed Protein fiber	2026-05-16
SRC-014	Spiber	Spiber Privacy Policy	2026-05-16

Disclaimer

This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.